OSRX

ImprimisRx Triumphs in High-Stakes Trademark Battle, Securing $34.9 Million Verdict Against OSRX and Ocular Science

by

NASHVILLE, Tenn. — In a decisive legal victory, ImprimisRx, a subsidiary of Harrow Health Inc., has won its trademark infringement case against OSRX, Inc. and its related entity, Ocular Science, Inc. A federal jury in San Diego awarded ImprimisRx $34.9 million after finding the defendants had willfully engaged in trademark infringement and unfair competition. This landmark case, tried in the United States District Court for the Southern District of California, concluded with unanimous decisions favoring ImprimisRx on all counts. The jury imposed $20.4 million in punitive damages and $14.5 million in actual damages, reflecting the … Read more

OSRX Vows to Fight Back After $34.9 Million Trademark Verdict Favors ImprimisRx in Heated Legal Battle

by

MISSOULA, Mont. — OSRX, Inc., based in Missoula, Montana, recently conveyed its profound dissatisfaction with a jury verdict that found it and its associate company, Ocular Science, Inc., liable for willful trademark infringement and unfair competition, resulting in a substantial penalty of $34.9 million in damages. The lawsuit, initiated by ImprimisRx, a subsidiary of Harrow Health, Inc., was adjudicated in the Southern District of California. Throughout the proceedings, OSRX defended its use of certain abbreviations commonly utilized in ophthalmology, such as “Pred,” “Moxi,” “Dex,” and “Brom,” which refer to prednisolone, moxifloxacin, dexamethasone, and bromfenac, respectively. … Read more